A clinical study of CYAD-221 in the treatment of B-cell malignancies
Latest Information Update: 22 Sep 2020
At a glance
- Drugs CYAD 221 (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 27 Mar 2019 New trial record
- 18 Mar 2019 According to a Celyad media release, this study is expected to begin by late 2020.